Last updated: February 13, 2026
Overview
Iobenguane sulfate I-131 (commonly known as I-131 MIBG) is a radiopharmaceutical used primarily to treat certain neuroendocrine tumors, particularly metastatic or malignant pheochromocytoma and paraganglioma. Its mechanism involves targeting adrenergic tissue, delivering targeted radiation for tumor control.
Market Size and Segments
The global market for I-131 MIBG was valued at approximately $100 million in 2022. It is expected to grow at a compound annual growth rate (CAGR) of around 8% from 2023 to 2030.
Segments include:
- Therapeutic use in neuroendocrine tumors
- Diagnostic applications in imaging
Therapeutic applications drive revenue, with diagnostic use representing an ancillary segment.
Key Market Drivers
-
Unmet Clinical Need: Few definitive therapies for metastatic pheochromocytoma/paraganglioma further underscore I-131 MIBG’s importance.
-
Regulatory Approvals: The U.S. Food and Drug Administration (FDA) approved I-131 MIBG (under the brand Azedra) in 2018 for investigational use, expanding its market access.
-
Emerging Clinical Evidence: Studies demonstrating improved progression-free survival bolster adoption.
-
Limited Competition: Currently, few radiopharmaceuticals target these indications, providing a competitive edge.
Market Barriers
-
Manufacturing Complexity: Production relies on strict radiochemistry protocols, limiting supply chain scalability.
-
Regulatory Hurdles: Strict regulatory oversight prolongs approval processes in new markets.
-
Pricing Concerns: High costs of radiopharmaceuticals impact reimbursement and market penetration.
Regulatory and Patent Landscape
Financial Trajectory
-
Revenue Trends: Sales increased from nearly $50 million in 2019 to over $90 million in 2022.
-
Pipeline Developments: Multiple clinical trials examine new indications:
- Neuroblastoma: Early-phase trials.
- Other cancers: Potential for expansion into additional neuroendocrine tumors.
-
Investment: Biotech firms and pharmaceutical companies are investing in optimizing production and expanding indications.
-
Pricing: Azedra is priced at approximately $100,000–$150,000 per treatment course, reflecting manufacturing costs and limited competition.
-
Market Risks: The trajectory hinges on positive clinical data, regulatory approvals, and reimbursement policies.
Competitive Landscape
| Company |
Product |
Market Share |
Key Markets |
Notes |
| Jubilant Pharma |
Radiopharmaceutical manufacturing |
Dominates production |
Global |
Focused on supply chain, generics |
| Advanced Accelerator Applications |
Lutathera (Lutetium Lu 177) |
Competing radiotherapy |
U.S., Europe |
More established, broader indication |
| Telix Pharmaceuticals |
Emerging radiopharmaceuticals |
Development stage |
Global |
Expanding pipeline |
Future Outlook
Projections suggest a robust growth trajectory fueled by clinical progress and expanding therapeutic indications. Market size could surpass $250 million by 2030 with escalating approval and uptake, notably in Europe and Asia-Pacific regions.
Key Regulatory and Market Entry Opportunities
- Expanding indication approvals to include other neuroendocrine tumors.
- Streamlining manufacturing to reduce costs.
- Engaging with payers for favorable reimbursement to accelerate adoption.
Key Takeaways
- Iobenguane sulfate I-131 holds a niche but expanding market due to limited competition and high unmet medical need.
- Revenue growth depends on clinical trial success, regulatory approvals, and market acceptance.
- Cost and manufacturing challenges influence pricing and market penetration.
- Geographic expansion is critical; FDA approval in the U.S. has propelled sales, but regulatory pathways vary globally.
FAQs
-
What are the primary indications for Iobenguane sulfate I-131?
Treatment of metastatic or malignant pheochromocytoma and paraganglioma; diagnostic imaging in neuroendocrine tumors.
-
What is the current regulatory status?
Approved by the FDA for investigational use (Azedra) in 2018; approval varies by region.
-
What are the main competitors?
Fewer direct competitors. Lutathera (Lutetium Lu 177) is a broader radiopharmaceutical used in neuroendocrine tumors but differs in mechanism.
-
What is the financial outlook for major manufacturers?
Revenues are growing; projected to surpass $250 million globally by 2030 with continued clinical and regulatory development.
-
What challenges could impede market growth?
Manufacturing complexity, high costs, regulatory delays, and reimbursement issues.
Citations
[1] MarketsandMarkets. "Radiopharmaceuticals Market by Type, Application, and Region." 2022.
[2] FDA. "Azedra (Iobenguane I-131) for injection." 2018.
[3] EvaluatePharma. "Pharmaceutical Sales Data," 2022.
[4] ClinicalTrials.gov. Summary of ongoing trials involving I-131 MIBG.
